Listed

Zimmer Biomet Holdings, Inc.

ZBHNYSECIK 1136869HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$2.18bnRevenue, Q2 FY2026, three months to 2026-06-30$2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$2.18bnRevenue, Q2 FY2026, three months to 2026-06-30$2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure+4.8% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin15.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $326.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure+0.5 pts on a year earlier
  • Net margin9.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $198.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure+1.8 pts on a year earlier
  • Diluted EPS$1.03Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure+33.8% on a year earlier
  • Free cash flow$393.6mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $447.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $54.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Report this figure+20.0% on a year earlier

Last eight quarters

Full statements
Revenue$2.18bnOperating margin 15.0%
Diluted EPS$1.03, Q2 FY2026
Free cash flow$393.6m, Q2 FY2026
Zimmer Biomet Holdings, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m1,824Revenue, Q3 FY2024, three months to 2024-09-30$1.82bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure2,023Revenue, Q4 FY2024, three months to 2024-12-31$2.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure1,909Revenue, Q1 FY2025, three months to 2025-03-31$1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure2,077Revenue, Q2 FY2025, three months to 2025-06-30$2.08bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure2,001Revenue, Q3 FY2025, three months to 2025-09-30$2.00bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure2,244Revenue, Q4 FY2025, three months to 2025-12-31$2.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure2,087Revenue, Q1 FY2026, three months to 2026-03-31$2.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure2,177Revenue, Q2 FY2026, three months to 2026-06-30$2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%15.3%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $279.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Revenue: $1.82bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure19.2%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $389.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Revenue: $2.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure15.3%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $292.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure14.4%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $300.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.08bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure17.6%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $351.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Revenue: $2.00bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure6.9%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $154.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Revenue: $2.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure17.9%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $373.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Revenue: $2.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure15.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $326.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure
Net margin%13.7%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $249.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Revenue: $1.82bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure11.8%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $239.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Revenue: $2.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure9.5%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $182.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Revenue: $1.91bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure7.4%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $152.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.08bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure11.5%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $230.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Revenue: $2.00bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figure6.2%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $139.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Revenue: $2.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure11.4%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $238.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Revenue: $2.09bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure9.1%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $198.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Revenue: $2.18bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure
Diluted EPS$ per share1.23Diluted EPS, Q3 FY2024, three months to 2024-09-30$1.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figurenot reported (Diluted EPS not reported)0.91Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure0.77Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.77 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure1.16Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-05, accession 0001193125-25-266884.Report this figurenot reported (Diluted EPS not reported)1.22Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.22 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure1.03Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-335044.Report this figure
Free cash flow$m351Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $395.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266884. Derived: 9-month figure less the 6-month figure.Capital expenditure: $44.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001193125-25-266884. Derived: 9-month figure less the 6-month figure.Report this figure455Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $506.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Capital expenditure: $51.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure338Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $382.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Capital expenditure: $44.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure328Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $378.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $50.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Report this figure364Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $418.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001193125-25-266884. Derived: 9-month figure less the 6-month figure.Capital expenditure: $55.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001193125-25-266884. Derived: 9-month figure less the 6-month figure.Report this figure443Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $517.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Capital expenditure: $74.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001193125-26-059853. Derived: 12-month figure less the 9-month figure.Report this figure323Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $359.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Capital expenditure: $36.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001193125-26-201710.Report this figure394Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $447.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Capital expenditure: $54.2m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-335044. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$8.23bnOperating margin 13.3%
Diluted EPS$3.55, FY2025
Free cash flow$1.47bn, FY2025
Zimmer Biomet Holdings, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m6,827Revenue, FY2021, twelve months to 2021-12-31$6.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0000950170-24-019353.Report this figure6,940Revenue, FY2022, twelve months to 2022-12-31$6.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000950170-25-026604.Report this figure7,394Revenue, FY2023, twelve months to 2023-12-31$7.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure7,679Revenue, FY2024, twelve months to 2024-12-31$7.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure8,232Revenue, FY2025, twelve months to 2025-12-31$8.23bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%12.6%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $860.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-23, accession 0000950170-24-019353.Revenue: $6.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0000950170-24-019353.Report this figure10.0%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $696.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-25, accession 0000950170-25-026604.Revenue: $6.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000950170-25-026604.Report this figure17.3%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $1.28bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $7.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure16.7%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $1.29bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $7.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure13.3%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $1.10bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $8.23bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure
Net margin%5.9%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $401.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-23, accession 0000950170-24-019353.Revenue: $6.83bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0000950170-24-019353.Report this figure3.3%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $231.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-25, accession 0000950170-25-026604.Revenue: $6.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-25, accession 0000950170-25-026604.Report this figure13.8%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $1.02bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $7.39bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure11.8%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $903.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $7.68bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure8.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $705.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001193125-26-059853.Revenue: $8.23bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure
Diluted EPS$ per share1.91Diluted EPS, FY2021, twelve months to 2021-12-31$1.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-23, accession 0000950170-24-019353.Report this figure1.10Diluted EPS, FY2022, twelve months to 2022-12-31$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-25, accession 0000950170-25-026604.Report this figure4.88Diluted EPS, FY2023, twelve months to 2023-12-31$4.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure4.43Diluted EPS, FY2024, twelve months to 2024-12-31$4.43 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure3.55Diluted EPS, FY2025, twelve months to 2025-12-31$3.55 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure
Free cash flow$m1,356Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $1.50bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2022-02-25, accession 0001564590-22-007160.Capital expenditure: $143.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-23, accession 0000950170-24-019353.Report this figure1,168Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $1.36bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. 10-K filed 2025-02-25, accession 0000950170-25-026604.Capital expenditure: $187.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-25, accession 0000950170-25-026604.Report this figure1,291Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $1.58bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001193125-26-059853.Capital expenditure: $291.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure1,296Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $1.50bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001193125-26-059853.Capital expenditure: $203.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure1,473Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.70bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001193125-26-059853.Capital expenditure: $224.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001193125-26-059853.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Zimmer Biomet Holdings, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Dodge & Cox2026-06-30$2.08bn24,124,735Added+582,035
BlackRock, Inc.2026-06-30$1.34bn15,614,847Added+274,041
HARRIS ASSOCIATES L P2026-06-30$1.10bn12,738,025Reduced−221,914
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.09bn12,634,937Reduced−158,475
Capital International Investors2026-06-30$1.05bn12,183,614Added+3,064,392
STATE STREET CORP2026-06-30$766.3m8,877,171Added+52,044
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$726.7m8,441,747Reduced−208,481
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$458.7m5,349,223Reduced−30,302
Invesco Ltd.2026-06-30$342.6m3,979,860Added+374,435
PRIMECAP MANAGEMENT CO/CA/2026-06-30$328.6m3,816,680Reduced−90,470

Recent filings

All 2,072 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Zimmer Biomet Holdings, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-0820:30 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-385256
2026-08-0520:11 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-335108
2026-08-0520:06 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-335044
2026-08-0510:30 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-333761
2026-06-2920:02 ET8-K1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits0001193125-26-288390
2026-05-2721:30 ET8-K5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001193125-26-242207
2026-05-1210:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-218098
2026-05-0121:11 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-201710
2026-04-2810:33 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-183430
2026-04-2810:30 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-183411

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 20, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1136869
Tickers
ZBH
Exchange
NYSE
SIC code
3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
ZIMMER HOLDINGS INC (to 2015-06-08)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. Listed shows no prices and gives no investment advice.